Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label irinotecan + temozolomide study in pediatric medulloblastoma and high-grade glioma
2006-005476-40Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2006
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan and temozolomide in medulloblastoma and glioma (2 arms), sponsored by Pfizer. Primary endpoint: Confirmed objective tumor response rate. Started Nov 2006; status: completed.
02
Drugs
irinotecantemozolomide
03
Conditions
medulloblastomaglioma
Beyond the preview
Go deeper on 2006-005476-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005476-40.